Thermo Fisher Scientific has obtained clearance from the FDA to market its CEDIA Buprenorphine II assay, designed to specifically detect buprenorphine and its three major metabolites. The immunoassay, which does not significantly cross-react with other opioids, has also received CE mark approval from European regulators, as well as registration in various EU countries, Australia, Canada and New Zealand.
Thermo Fisher secures clearances, registration for buprenorphine assay
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.